Novel applications of recombinant erythropoietin.
Curr Opin Pharmacol
; 6(2): 184-9, 2006 Apr.
Article
em En
| MEDLINE
| ID: mdl-16483842
ABSTRACT
Recombinant erythropoietin (EPO) was introduced into clinical practice after the identification of EPO as the major haemopoietic growth factor determining survival and maturation of erythroid precursors. Advances in our understanding of the novel sites of action of EPO in the vasculature, brain, heart and kidney have opened new avenues of therapeutic potential for EPO, and have led to an increased understanding of the biological roles of EPO and its mechanisms of cell protection.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Eritropoetina
/
Infarto do Miocárdio
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article